NEPAL (Neuromodulatory Examination of Pain and Mobility Across the Lifespan)
NEPAL
Neuroimaging Age-related Versus Pain-related Changes in Pain Modulation
4 other identifiers
observational
105
1 country
4
Brief Summary
Musculoskeletal pain represents the leading cause of disability worldwide. It has been traditionally attributed to peripheral mechanisms, but peripheral damage, inflammation, and psychological factors have failed to significantly account for the presence, absence, or severity of chronic musculoskeletal pain (CMP). Recent studies show that individuals with CMP exhibit dysfunctional pain modulation supporting a significant central nervous system (CNS) contribution. However, the CNS mechanisms underlying these changes in pain modulation are not currently known, nor is their relation to clinical pain progression. The proposed pilot examines brain circuits recently described in predicting the transition from acute to chronic pain, in predicting clinical and experimental pain changes as well as physical performance and mobility changes in older persons with musculoskeletal pain over a one year period. The findings will provide novel and important information regarding the mechanisms underlying aberrant pain processing and its functional consequences in older adults with musculoskeletal pain. The information learned can be subsequently used to target treatment and prevention strategies in future studies of older adults. The central hypothesis is that increased functional and structural connectivity of cortico-striatal regions will be significantly associated with baseline clinical and experimental pain and decreased physical function in persons with CMP and will account for more rapid clinical pain and disability progression over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2015
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 23, 2014
CompletedStudy Start
First participant enrolled
July 1, 2015
CompletedFirst Posted
Study publicly available on registry
July 2, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 4, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 4, 2024
CompletedResults Posted
Study results publicly available
March 18, 2025
CompletedMarch 18, 2025
March 1, 2025
8.6 years
December 23, 2014
February 3, 2025
March 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Short Physical Performance Battery (SPPB)
The Short Physical Performance Battery (SPPB) Total Score is a measure of physical function. It is calculated by summing three measures of lower-extremity function: standing balance (side-by-side, semi-tandem, and tandem stance), 4-meter walking speed, and ability to rise from a chair. Each task is rated on a 0-4 scale, with increasing scores indicating better physical performance. The SPPB Total scores range from 0-12.
At baseline-physical function visit
Study Arms (3)
Older Adults with Musculoskeletal Pain
Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
Older Adults without Musculoskeletal Pain
Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
Young Controls
Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
Interventions
MRI scans utilized to measure the structural and functional integrity of the brain.
Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A\&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
Eligibility Criteria
Older adults (60+ years old) who experience musculoskeletal pain as well as those who do not experience musculoskeletal pain; healthy young adults (18-25 years old).
You may qualify if:
- older adults over 60 years of age with and without musculoskeletal pain
- healthy young adults between the ages of 18-25
You may not qualify if:
- pregnant women
- history of alcohol/drug abuse in the past
- known intra-cerebral pathology or epilepsy
- significant cognitive impairment as evidenced by the 3MS
- hospitalizations for mental health reasons in the past year
- not meeting MRI screening requirements (implants, prosthesis, artificial limb/joint, shunt, metal rods, hearing aid, claustrophobia or anxiety)
- chronic/current use of narcotic medications
- serious systemic (uncontrolled diabetes; self reported A1C\>7), neurological , or cardiovascular disease (uncontrolled hypertension \>155/90)
- liver or kidney disease
- inability to consent for study participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Floridalead
- National Institute on Aging (NIA)collaborator
- National Institutes of Health (NIH)collaborator
Study Sites (4)
UF & Shands Orthopaedics and Sports Medicine Institute
Gainesville, Florida, 32607, United States
UF Health Science Center
Gainesville, Florida, 32608, United States
Clinical Translational Research Building
Gainesville, Florida, 32611, United States
McKnight Brain Institute of the University of Florida
Gainesville, Florida, 32611, United States
Biospecimen
Blood plasma
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Eric Weber
- Organization
- University o fFlorida
Study Officials
- PRINCIPAL INVESTIGATOR
Yenisel Cruz-Almeida, MSPH, PhD
University of Florida
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 23, 2014
First Posted
July 2, 2015
Study Start
July 1, 2015
Primary Completion
February 4, 2024
Study Completion
February 4, 2024
Last Updated
March 18, 2025
Results First Posted
March 18, 2025
Record last verified: 2025-03